RBC Capital raised the firm’s price target on Sage Therapeutics to $26 from $21 and keeps a Sector Perform rating on the shares. The company’s Q4 results saw solid early patient numbers for Zurzuvae postpartum depression launch and reasonably favorable initial metrics around prescriber base, payer dynamics, and anecdotal experience, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
- Bad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been Added
- Sage Therapeutics expects cash available will support its operations into 2026
- Sage Therapeutics reports Q4 EPS (55c), consensus ($1.28)
- SAGE Earnings this Week: How Will it Perform?
- Sage Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
